TSE:4151Pharmaceuticals
Kyowa Kirin (TSE:4151) Valuation Check After Rocatinlimab Trials Are Halted Over Safety Concerns
Kyowa Kirin (TSE:4151) has moved to discontinue all clinical trials of rocatinlimab after a planned safety review highlighted malignancy concerns linked to OX40 pathway modulation, including confirmed and suspected Kaposi’s sarcoma cases.
See our latest analysis for Kyowa Kirin.
At a share price of ¥2,339, Kyowa Kirin has seen a 1-day share price return of 1.56% and a 7-day gain of 3.89%, compared with a weaker 30-day share price return of a 10.11% decline and a year-to-date share price...